Abstract | Background/Aims: Methods: A retrospective multicenter cohort study was conducted involving patients with Crohn's disease (CD) or ulcerative colitis (UC) from 10 referral hospitals in Korea who discontinued firstline anti-TNF therapy after achieving clinical remission. Results: A total of 109 IBD patients (71 CD and 38 UC) with a median follow-up duration of 56 months were analyzed. The cumulative relapse rates at 1, 3, and 5 years were 11.3%, 46.7%, and 62.5% for CD patients and 28.9%, 45.3%, and 60.9% for UC patients. Multivariable Cox analysis revealed that discontinuation owing to the clinician's decision was associated with lower risk of relapse (vs patient's preference: hazard ratio [HR], 0.13; 95% confidence interval [CI], 0.04 to 0.48; p=0.002) and adalimumab use was associated with higher risk of relapse (vs infliximab: HR, 4.42; 95% CI, 1.24 to 17.74; p=0.022) in CD patients. Mucosal healing was associated with lower risk of relapse (vs nonmucosal healing: HR, 0.12; 95% CI, 0.02 to 0.83; p=0.031) in UC patients. Anti-TNF re-induction was provided to 52 patients, and a response was obtained in 50 patients. However, 25 of them discontinued retreatment owing to a loss of response (n=15), the patient's preference (n=6), and other factors (n=4). Conclusions: More than 60% of IBD patients in remission under anti-TNF therapy relapsed within 5 years of treatment cessation. Anti-TNF re-induction was effective. However, half of the patients discontinued anti-TNF therapy, and 50% of these patients discontinued treatment owing to loss of response.
|
Authors | Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im, Chang Hwan Choi, IBD Research Group of the Korean Association for the Study of Intestinal Diseases |
Journal | Gut and liver
(Gut Liver)
Vol. 15
Issue 5
Pg. 752-762
(09 15 2021)
ISSN: 2005-1212 [Electronic] Korea (South) |
PMID | 33767028
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Tumor Necrosis Factor Inhibitors
- Tumor Necrosis Factor-alpha
- Infliximab
- Adalimumab
|
Topics |
- Adalimumab
- Cohort Studies
- Colitis, Ulcerative
(drug therapy)
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Infliximab
- Remission Induction
- Republic of Korea
- Retrospective Studies
- Tumor Necrosis Factor Inhibitors
- Tumor Necrosis Factor-alpha
|